Lion Group Holding Ltd. - American Depositary Share (LGHL)
3.6783
+0.5283 (16.77%)
NASDAQ · Last Trade: Apr 4th, 8:20 PM EDT
Detailed Quote
Previous Close
3.150
Open
3.100
Bid
3.430
Ask
3.600
Day's Range
3.000 - 3.900
52 Week Range
2.820 - 42.99
Volume
508,949
Market Cap
64.00M
PE Ratio (TTM)
-0.6192
EPS (TTM)
-5.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
80,311
Chart
About Lion Group Holding Ltd. - American Depositary Share (LGHL)
Lion Group Holding Ltd is a diversified financial services company that primarily focuses on the provision of trading solutions and investment services to retail and institutional clients. The company operates through various platforms, offering access to a range of financial products, including cryptocurrencies, foreign exchange, and other assets. Lion Group is dedicated to technology-driven solutions, aiming to enhance the trading experience for its users while also providing educational resources to help clients navigate the complexities of the financial markets. With a focus on innovation and customer satisfaction, Lion Group seeks to establish a strong presence in the evolving landscape of digital finance. Read More
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 114% to $1.47. Palisade Bio transformed GI-focused pipeline through exclusive worldwide licensing agreement with Giiant Pharma, Inc. for multiple oral drug candidates targeting inflammatory bowel disease.
